Macroaxis Story

Macroaxis News
  
By Vlad Skutelnik

August 22, 2019

Today I will concentrate on 8 Compulsion isntruments to have in your portfolio in September 2019. I will cover Constellation Brands, Lindsay Corporation, Anheuser Busch Inbev SA Sponsor, Bristol Myers Squibb Company, Merck Company, Astrazeneca PLC, Philip Morris International, and British American Tobacco Indus
The Top 8 Compulsion stocks to own in September 2019

This list of potential positions covers Addiction driven consumer products and services. Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.


Constellation Brands (STZ)

The company has Net Profit Margin of 29.96 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 36.82 % which entails that for every 100 dollars of revenue it generated 0.37 of operating income. The entity currently falls under 'Large-Cap' category with total capitalization of 39.53B. Constellation Brands shows prevailing Real Value of $190.86 per share. The current price of the firm is $205.75. At this time the firm appears to be overvalued. This module approximates value of Constellation Brands from analyzing the firm fundamentals such as Return On Equity of 21.48%, Profit Margin of 29.96% and Current Valuation of 53.23B as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend. Constellation Brands shows prevailing Real Value of $190.86 per share. The current price of the firm is $205.75. At this time the firm appears to be overvalued. This module approximates value of Constellation Brands from analyzing the firm fundamentals such as Current Valuation of 53.23B, Return On Equity of 21.48% and Profit Margin of 29.96% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Lindsay Corporation (LNN)

The company has Net Profit Margin of 1.21 % which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 4.88 % which entails that for every 100 dollars of revenue it generated 0.05 of operating income. The entity currently falls under 'Small-Cap' category with total capitalization of 994.43M.
Total Debt
Lindsay secures last-minute Real Value of $92.51 per share. The latest price of the firm is $94.45. At this time the firm appears to be fairly valued. This module forecasts value of Lindsay from analyzing the firm fundamentals such as Profit Margin of 1.21%, Return On Equity of 2.06% and Current Valuation of 985.84M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend to purchase undervalued stocks and to get rid of overvalued stocks since at some point entities prices and their ongoing real values will merge together.

Anheuser Busch Inbev SA Sponsor (BUD)

The company has Net Profit Margin of 13.81 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 41.64 % which entails that for every 100 dollars of revenue it generated 0.42 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 187.58B. Anheuser Busch Inbev shows prevailing Real Value of $116.14 per share. The current price of the firm is $96.97. At this time the firm appears to be undervalued. This module approximates value of Anheuser Busch Inbev from analyzing the firm fundamentals such as Return On Equity of 11.38% and Profit Margin of 13.81% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend. Anheuser Busch competes with Compania Cervecerias, Fomento Economico, Ambev S, Craft Brew, LSB Industries, Sony, Orix Corp, and TOYO SUISAN. Anheuser-Busch InBev SANV, a brewing company, engages in the production, distribution, and sale of beer, alcoholic beverages, and soft drinks. The company was founded in 1366 and is headquartered in Leuven, Belgium. Anheuser Busch operates under Beverages - Brewers classification in USA and is traded on BATS Exchange. It employs 175000 people.

Bristol Myers Squibb Company (BMY)

The company has Net Profit Margin of 26.0 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 32.08 % which entails that for every 100 dollars of revenue it generated 0.32 of operating income. The entity currently falls under 'Large-Cap' category with total capitalization of 79.1B.
Total Debt
Bristol Myers competes with Astrazeneca PLC, Hutchison China, Novartis, Merck, GlaxoSmithKline PLC, Pfizer, GW Pharmaceuticals, Johnson Johnson, and Eli Lilly. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on BATS Exchange. It employs 23300 people.

Merck Company (MRK)

The company has Net Profit Margin of 21.1 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 38.73 % which entails that for every 100 dollars of revenue it generated 0.39 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 208.92B. Merck secures last-minute Real Value of $85.57 per share. The latest price of the firm is $82.51. At this time the firm appears to be fairly valued. This module forecasts value of Merck from analyzing the firm fundamentals such as Profit Margin of 21.10%, Current Valuation of 234.3B and Return On Equity of 30.55% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend to purchase undervalued stocks and to get rid of overvalued stocks since at some point entities prices and their ongoing real values will merge together. Merck competes with Astrazeneca PLC, Hutchison China, Novartis, GlaxoSmithKline PLC, Pfizer, GW Pharmaceuticals, Bristol Myers, and Johnson Johnson. It operates through four segments Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug Manufacturers - Major classification in USA and is traded on BATS Exchange. It employs 69000 people.

Astrazeneca PLC (AZN)

The company has Net Profit Margin of 9.48 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 22.62 % which entails that for every 100 dollars of revenue it generated 0.23 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 113.14B.
Total Debt

Philip Morris International (PM)

The company has Net Profit Margin (PM) of 26.58 % which may suggest that it has a good control over its expenditures, executes well on its competitive polices, or have a solid pricing strategies. This is very large. Likewise, it shows Net Operating Margin (NOM) of 40.88 % which signify that for every $100 of sales it has a net operating income of 0.41. The entity currently falls under 'Mega-Cap' category with market capitalization of 113.65B. Philip Morris Intern holds recent Real Value of $84.78 per share. The prevailing price of the company is $72.02. At this time the company appears to be undervalued. This module determines value of Philip Morris Intern from analyzing the company fundamentals such as Return On Equity of 0.06%, Shares Outstanding of 1.56B and Operating Margin of 40.88% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.

British American Tobacco Indus (BTI)

The company has Return on Asset of 4.35 % which means that on every $100 spent on asset it made $4.35 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 9.88 % implying that it generated $9.88 on every 100 dollars invested. This firm currently falls under 'Large-Cap' category with total capitalization of 80B.
Total Debt
British American Tob shows prevailing Real Value of $42.07 per share. The current price of the firm is $36.84. At this time the firm appears to be undervalued. This module approximates value of British American Tob from analyzing the firm fundamentals such as Return On Equity of 9.88%, Shares Outstanding of 2.29B and Profit Margin of 24.60% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Current 8 Compulsion Recommendations

Competition Technical Indicators

Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
 6.63  0.83  0.08 (11.91)  9.40  0.08 (7.07)  12.26 (13.18)  49.95 
 1.43 (0.08)  0.00 (0.19)  0.00 (0.0482)  0.00  2.27 (3.12)  15.97 
 9.10  2.39  0.07 (0.36)  10.14  0.10 (35.59)  20.00 (20.00)  162.13 
 0.97 (0.08)  0.00 (0.14)  0.00 (0.08)  0.00  1.73 (2.11)  6.57 
 1.35  0.05  0.02  0.23  1.76  0.0156 (1.46)  2.94 (3.24)  12.23 
 1.18 (0.32)  0.00 (1.43)  0.00 (0.22)  0.00  1.73 (3.60)  7.69 
 1.12 (0.02)  0.00 (0.12)  0.00 (0.0283)  0.00  2.33 (2.80)  10.45 
 0.00  0.00  0.00  0.00  0.00  0.00  0.00  0.00  0.00  0.00 
 1.09  0.22  0.16  0.64  1.02  0.11 (1.25)  1.64 (1.97)  13.60 
 1.13  0.21  0.15 (12.49)  1.00  0.1 (1.42)  2.95 (1.98)  11.89 

About Contributor

Vlad Skutelnik
   Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered as solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Macroaxis. Please refer to our Terms of Use for any information regarding our disclosure principles.

Did you try this?

Run Aroon Oscillator Now

   

Aroon Oscillator

Analyze current equity momentum using Aroon Oscillator and other momentum ratios
All  Next Launch Module
See also Stocks Correlation. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.
Search macroaxis.com